Medivir

Medivir has chosen the Waters Corp. Synapt HDMS System to hasten its drug discovery efforts in the area of protease inhibitor research and eventually help patients who suffer with herpes, hepatitis C, HIV, osteoporosis, osteoarthritis, and high blood pressure. Installed in June, the Synapt High Definition Mass Spectrometry (MS) System is yielding significant information that is assisting with the decision-making process and helping Medivir reach its drug discovery milestones. In terms of helping Medivir advance its research, the Synapt HDMS System carries great potential.